NASDAQ:HSKA Heska - HSKA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Heska Co. Please log in to your account or sign up in order to add this asset to your watchlist. $86.29 -2.19 (-2.48%) (As of 02/6/2023 12:00 AM ET) Add Compare Share Share Today's Range$85.92▼$89.7050-Day Range$60.21▼$93.1552-Week Range$57.83▼$154.85Volume134,360 shsAverage Volume138,432 shsMarket Capitalization$934.52 millionP/E RatioN/ADividend YieldN/APrice Target$123.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Heska MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside42.5% Upside$123.00 Price TargetShort InterestHealthy4.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.75Based on 3 Articles This WeekInsider TradingAcquiring Shares$851,037 Bought Last QuarterProj. Earnings Growth120.00%From $0.30 to $0.66 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.76 out of 5 starsMedical Sector41st out of 1,027 stocksDiagnostic Substances Industry2nd out of 15 stocks 3.3 Analyst's Opinion Consensus RatingHeska has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $123.00, Heska has a forecasted upside of 42.5% from its current price of $86.29.Amount of Analyst CoverageHeska has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.52% of the float of Heska has been sold short.Short Interest Ratio / Days to CoverHeska has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Heska has recently decreased by 10.01%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHeska does not currently pay a dividend.Dividend GrowthHeska does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HSKA. Previous Next 3.2 News and Social Media Coverage News SentimentHeska has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Heska this week, compared to 2 articles on an average week.Search Interest2 people have searched for HSKA on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Heska to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Heska insiders have bought more of their company's stock than they have sold. Specifically, they have bought $851,037.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders11.00% of the stock of Heska is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.01% of the stock of Heska is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Heska are expected to grow by 120.00% in the coming year, from $0.30 to $0.66 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Heska is -54.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Heska is -54.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHeska has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Heska (NASDAQ:HSKA) StockHeska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through the North America and International segments. The North America segment includes the United States, Canada, and Mexico. The International segment involves Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company was founded by Robert B. Grieve and Lynnor B. Stevenson in 1988 and is headquartered in Loveland, CO.Read More Receive HSKA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heska and its competitors with MarketBeat's FREE daily newsletter. Email Address HSKA Stock News HeadlinesJanuary 31, 2023 | americanbankingnews.comHead to Head Analysis: Virax Biolabs Group (NASDAQ:VRAX) vs. Heska (NASDAQ:HSKA)January 28, 2023 | americanbankingnews.comHeska Co. (NASDAQ:HSKA) Receives Average Rating of "Hold" from BrokeragesFebruary 6, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 18, 2023 | finance.yahoo.comIs There An Opportunity With Heska Corporation's (NASDAQ:HSKA) 50% Undervaluation?January 11, 2023 | finance.yahoo.comHeska (HSKA) Moves 9.0% Higher: Will This Strength Last?January 3, 2023 | finance.yahoo.comHeska Corporation Completes Acquisition of LightDeck DiagnosticsDecember 23, 2022 | finance.yahoo.comHeska to Participate in the 41st J.P. Morgan Annual Healthcare ConferenceNovember 8, 2022 | finance.yahoo.comHeska Corporation Reports Third Quarter 2022 ResultsFebruary 6, 2023 | Investing Trends (Ad)New "Vertical" Technology Solves Solar Power's Major FlawEven conservationists hate conventional solar farms. That's because they take up too much land and can degrade the environment. And let's face it, land is expensive...Fortunately, new groundbreaking tower technology solves solar's #1 drawback. These unique vertical structures not only take up to 90% less land space, but also generate extra electric power.November 8, 2022 | finance.yahoo.comHeska (HSKA) Q3 Earnings and Revenues Lag EstimatesNovember 8, 2022 | finance.yahoo.comWill Heska Corporation (HSKA) Overcome the Current Challenges?November 1, 2022 | finance.yahoo.comHeska (HSKA) Reports Next Week: Wall Street Expects Earnings GrowthOctober 19, 2022 | globenewswire.comNORDIC Veterinary Diagnostics Market to Garner around USD 167 Million by 2031 and to Grow with a CAGR of ~7% during 2022-2031; Rising Number of Pets to Elevate Market Growth – Kenneth Research - GlobeNewswireOctober 18, 2022 | globenewswire.comGlobal Veterinary Vaccines Market to Reach $13.3 Billion by 2027 - GlobeNewswireOctober 18, 2022 | benzinga.comHeska Third Quarter 2022 Financial Results and Earnings Call Scheduled for November 8, 2022 - Heska (NASD - BenzingaOctober 18, 2022 | finance.yahoo.comHeska Third Quarter 2022 Financial Results and Earnings Call Scheduled for November 8, 2022October 12, 2022 | businesswire.comVeterinary Diagnostics Market Report 2022: Growing Prevalence of Zoonotic Diseases to Drive Growth - ResearchAndMarkets.com - Business WireOctober 11, 2022 | finance.yahoo.comThe past year for Heska (NASDAQ:HSKA) investors has not been profitableOctober 6, 2022 | finance.yahoo.comDemand for Global Animal Health Market Size to Surpass USD 87.07 Billion by 2026, Exhibit a CAGR of 8.7% - Comprehensive Research Report by Facts & Factors - Yahoo FinanceOctober 2, 2022 | reuters.comHSKA.OQ - Heska Corp | Stock Price & Latest News | ReutersSeptember 30, 2022 | finance.yahoo.comVeterinary Infectious Disease Diagnostics Global Market Report 2022: Featuring Zoetis, IDEXX, Thermo Fisher, Randox & Others - Yahoo FinanceSeptember 22, 2022 | reuters.comHSKA.O - Heska Corp | Stock Price & Latest News | ReutersSeptember 17, 2022 | nasdaq.comIs There An Opportunity With Heska Corporation's (NASDAQ:HSKA) 33% Undervaluation? - NasdaqSeptember 16, 2022 | nasdaq.comIs There An Opportunity With Heska Corporation's (NASDAQ:HSKA) 33% Undervaluation?September 12, 2022 | nasdaq.comHeska To Buy LightDeck For Purchase Price Of $38.7 Mln - Quick FactsSeptember 12, 2022 | finance.yahoo.comHeska to Acquire LightDeck Diagnostics to Invest in Manufacturing Capabilities and Accelerate Research and Development EffortsSeptember 7, 2022 | businesswire.comWorldwide Veterinary Care Industry to 2027 - Featuring Ceva Sant Animale, Zoetis, Elanco and Heska Among Others - ResearchAndMarkets.com - Business WireSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HSKA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heska and its competitors with MarketBeat's FREE daily newsletter. Email Address HSKA Company Calendar Last Earnings11/08/2022Today2/06/2023Next Earnings (Estimated)2/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HSKA CUSIPN/A CIK1038133 Webwww.heska.com Phone(970) 493-7272Fax970-619-3003Employees655Year FoundedN/APrice Target and Rating Average Stock Price Forecast$123.00 High Stock Price Forecast$165.00 Low Stock Price Forecast$58.00 Forecasted Upside/Downside+42.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.57) Trailing P/E RatioN/A Forward P/E Ratio287.63 P/E GrowthN/ANet Income$-1,150,000.00 Net Margins-6.26% Pretax Margin-7.34% Return on Equity0.09% Return on Assets0.06% Debt Debt-to-Equity Ratio0.24 Current Ratio7.18 Quick Ratio5.61 Sales & Book Value Annual Sales$253.74 million Price / Sales3.68 Cash Flow$1.02 per share Price / Cash Flow84.48 Book Value$40.69 per share Price / Book2.12Miscellaneous Outstanding Shares10,830,000Free Float9,635,000Market Cap$934.52 million OptionableNot Optionable Beta1.54 Key ExecutivesKevin S. WilsonPresident, Chief Executive Officer & DirectorNancy WisnewskiChief Operating Officer & Executive Vice PresidentCatherine I. GrassmanChief Financial Officer & Executive Vice PresidentGlenn R. FrankVice President-Research & DevelopmentSteven M. EylChief Commercial Officer & Executive VPKey CompetitorsMeridian BioscienceNASDAQ:VIVOMyriad GeneticsNASDAQ:MYGNCelldex TherapeuticsNASDAQ:CLDXIntellia TherapeuticsNASDAQ:NTLACollegium PharmaceuticalNASDAQ:COLLView All CompetitorsInsiders & InstitutionsMonarch Partners Asset Management LLCSold 18,368 shares on 2/2/2023Ownership: 0.239%SG Americas Securities LLCSold 8,203 shares on 2/2/2023Ownership: 0.029%Signaturefd LLCBought 237 shares on 1/30/2023Ownership: 0.004%Rice Hall James & Associates LLCSold 471 shares on 1/27/2023Ownership: 0.420%Inspire Investing LLCBought 983 shares on 1/26/2023Ownership: 0.035%View All Insider TransactionsView All Institutional Transactions HSKA Stock - Frequently Asked Questions Should I buy or sell Heska stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heska in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HSKA shares. View HSKA analyst ratings or view top-rated stocks. What is Heska's stock price forecast for 2023? 4 Wall Street research analysts have issued 12-month price objectives for Heska's stock. Their HSKA share price forecasts range from $58.00 to $165.00. On average, they expect the company's stock price to reach $123.00 in the next twelve months. This suggests a possible upside of 42.5% from the stock's current price. View analysts price targets for HSKA or view top-rated stocks among Wall Street analysts. How have HSKA shares performed in 2023? Heska's stock was trading at $62.16 at the beginning of 2023. Since then, HSKA shares have increased by 38.8% and is now trading at $86.29. View the best growth stocks for 2023 here. When is Heska's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023. View our HSKA earnings forecast. How were Heska's earnings last quarter? Heska Co. (NASDAQ:HSKA) announced its quarterly earnings results on Tuesday, November, 8th. The medical research company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.09 by $0.15. The medical research company earned $61.49 million during the quarter, compared to analyst estimates of $69.72 million. Heska had a positive trailing twelve-month return on equity of 0.09% and a negative net margin of 6.26%. What guidance has Heska issued on next quarter's earnings? Heska issued an update on its FY 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $266.43 million-$266.43 million, compared to the consensus revenue estimate of $272.89 million. What is Kevin S. Wilson's approval rating as Heska's CEO? 5 employees have rated Heska Chief Executive Officer Kevin S. Wilson on Glassdoor.com. Kevin S. Wilson has an approval rating of 57% among the company's employees. This puts Kevin S. Wilson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Heska own? Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Exxon Mobil (XOM), Netflix (NFLX), Biogen (BIIB), AbbVie (ABBV), Amgen (AMGN), Broadcom (AVGO), Alibaba Group (BABA), Exelixis (EXEL) and Merck & Co., Inc. (MRK). What is Heska's stock symbol? Heska trades on the NASDAQ under the ticker symbol "HSKA." Who are Heska's major shareholders? Heska's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Riverbridge Partners LLC (2.92%), Assenagon Asset Management S.A. (1.18%), Manning & Napier Group LLC (0.62%), Rice Hall James & Associates LLC (0.42%), Monarch Partners Asset Management LLC (0.24%) and Yousif Capital Management LLC (0.06%). Insiders that own company stock include Bonnie J Trowbridge, Catherine Grassman, Jason D Aroesty, Kevin S Wilson, Nancy Wisnewski and Sharon J Larson. View institutional ownership trends. How do I buy shares of Heska? Shares of HSKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Heska's stock price today? One share of HSKA stock can currently be purchased for approximately $86.29. How much money does Heska make? Heska (NASDAQ:HSKA) has a market capitalization of $934.52 million and generates $253.74 million in revenue each year. The medical research company earns $-1,150,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. How many employees does Heska have? The company employs 655 workers across the globe. How can I contact Heska? Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The official website for the company is www.heska.com. The medical research company can be reached via phone at (970) 493-7272, via email at investorrelations@heska.com, or via fax at 970-619-3003. This page (NASDAQ:HSKA) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.